List of Excipients in Branded Drug CARAFATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ATLANTIC BIOLOGICALS CORP	CARAFATE	sucralfate	17856-0170	FD&C RED NO. 40
ATLANTIC BIOLOGICALS CORP	CARAFATE	sucralfate	17856-0170	GLYCERIN
ATLANTIC BIOLOGICALS CORP	CARAFATE	sucralfate	17856-0170	METHYLPARABEN
ATLANTIC BIOLOGICALS CORP	CARAFATE	sucralfate	17856-0170	SORBITOL
ATLANTIC BIOLOGICALS CORP	CARAFATE	sucralfate	17856-0170	WATER

CARAFATE Excipient Strategy and Commercial Opportunities for Sucralfate Products

Last updated: August 14, 2026

Carafate is the branded formulation of sucralfate, an aluminum sucrose octasulfate used for short-term treatment of active duodenal ulcers and maintenance therapy after healing. The active ingredient is off-patent, and commercial value is concentrated in dosage-form execution: suspension stability, redispersibility, palatability, dose convenience, manufacturing consistency, and differentiated packaging.

The strongest opportunities are sugar-free ready-to-use liquids, unit-dose administration, improved suspension performance, hospital and institutional packaging, and specialty veterinary products. Biosimilar risk is irrelevant because sucralfate is a small-molecule drug. Generic competition is established, so a new entrant requires either cost leadership, a differentiated formulation, or a regulatory strategy that supports a meaningful product distinction.

What is Carafate and how does sucralfate work?

Carafate contains sucralfate, a locally acting gastrointestinal drug. In an acidic environment, sucralfate forms a viscous, negatively charged polymer that binds to positively charged proteins at ulcer sites and creates a protective barrier. Systemic exposure is limited because the compound is minimally absorbed from the gastrointestinal tract. [1]

The U.S. Carafate label includes two principal dosage forms:

Product	Strength	Administration	Primary commercial issue
Carafate tablets	1 gram per tablet	Oral tablet	Swallowability and timing burden
Carafate oral suspension	1 gram per 10 mL	Oral liquid	Sedimentation, redispersibility, taste and packaging

The labeled regimen is commonly 1 gram four times daily for active duodenal ulcer treatment, taken on an empty stomach. The dosing schedule creates an adherence problem and increases the importance of convenient packaging and clear administration instructions. [1]

What excipients are used in Carafate formulations?

Carafate tablet excipients

The Carafate tablet formulation uses conventional solid-dose excipients, including:

• Colloidal silicon dioxide
• Hypromellose
• Magnesium stearate
• Microcrystalline cellulose
• Povidone
• Sodium starch glycolate

These excipients support powder flow, granulation or compression, tablet integrity, lubrication, and disintegration. They are not the main source of differentiation because they are widely used in generic tablet manufacturing.

The commercial challenge is not chemical novelty. It is achieving tablet hardness, low friability, acceptable disintegration, and consistent sucralfate content despite the high drug load. A 1-gram tablet has limited room for excipient optimization without increasing tablet size.

Carafate suspension excipients

The oral suspension label identifies a structured aqueous vehicle containing excipients such as:

• Glycerin
• Hydroxyethyl cellulose
• Methylparaben
• Microcrystalline cellulose and carboxymethylcellulose sodium
• Sodium phosphate
• Sorbitol
• Xanthan gum
• Purified water

The suspension system performs several functions:

1. Maintains sucralfate particles in a pourable vehicle.
2. Limits hard-cake formation during storage.
3. Enables redispersion after shaking.
4. Provides viscosity and mouthfeel.
5. Controls microbial growth.
6. Adjusts sweetness and palatability.
7. Maintains product stability across the labeled storage period.

The excipient system is commercially more important in the liquid product than in the tablet. Sucralfate is a high-dose, poorly soluble material. The formulation must suspend the active rather than dissolve it, which increases the risk of sedimentation, dose nonuniformity and inaccurate dosing after storage.

How should an excipient strategy be designed for sucralfate suspension?

A sucralfate suspension strategy should focus on physical stability rather than solubility enhancement. The target is a suspension that settles slowly, does not form an irreversible cake and redistributes with ordinary patient shaking.

Suspending-agent system

Hydroxyethyl cellulose, xanthan gum and microcrystalline cellulose-carboxymethylcellulose systems can provide different viscosity and yield-stress profiles. The preferred system depends on:

• Particle-size distribution of sucralfate
• Sedimentation rate
• Redispersibility
• Pourability through the bottle neck
• Dose uniformity during the final doses
• Temperature sensitivity
• Interaction with preservatives and flavoring agents

Excess viscosity can improve physical stability but create poor pourability and inaccurate dosing. A suspension that requires vigorous shaking or produces a slow, irregular pour can undermine adherence.

Wetting and dispersion

Sucralfate particles must be uniformly wetted during manufacturing. Poor wetting can cause agglomeration, floating particles or delayed dispersion. Controlled addition of the active to the vehicle, high-shear mixing and defined particle-size controls are more important than simply increasing polymer concentration.

Preservative selection

Methylparaben is used in the branded suspension. A reformulator could evaluate alternative preservative systems, including combinations based on parabens, benzoates or sorbates, subject to pH, microbial challenge testing, packaging compatibility and regulatory acceptability.

A preservative-free formulation could have commercial value for patients with preservative sensitivity, but it would require a robust microbial-control strategy. Unit-dose packaging, aseptic manufacture or a shorter in-use period may be necessary.

Sweetener and flavor system

Sorbitol contributes sweetness and mouthfeel. It can also create a gastrointestinal tolerance issue at higher exposure in sensitive patients. Opportunities include:

• Lower-sorbitol formulations
• Sugar-free systems with alternative sweeteners
• Reduced-flavor products for adult institutional use
• Pediatric-oriented flavor systems, subject to clinical and regulatory support
• Flavor systems that mask mineral or chalky notes

Taste optimization should not increase viscosity, alter preservative performance or compromise sucralfate dispersion.

What formulation patents protect Carafate and generic sucralfate products?

The active-ingredient opportunity is mature. Sucralfate was approved decades ago, and the original compound and basic dosage-form protections are no longer the principal commercial barrier.

The relevant intellectual-property categories are likely to be:

IP category	Commercial relevance
Sucralfate composition claims	Low for new entrants because of product age
Basic tablet formulation claims	Generally limited, subject to claim-by-claim review
Suspension vehicle claims	Potentially relevant for differentiated liquid products
Particle-size and process claims	Can protect manufacturing consistency or physical stability
Packaging claims	Relevant for unit-dose or reconstitution systems
Method-of-use claims	Potentially relevant only for specific protected indications or dosing regimens
Trade dress and trademarks	Relevant to Carafate branding, not generic entry

A new product should be screened against formulation, process, packaging and method-of-use patents rather than assuming that the absence of active-ingredient patents eliminates all risk. The practical barrier in sucralfate is generally formulation development and ANDA execution, not biosimilar-style molecule protection.

What is the FDA regulatory status of Carafate?

Carafate is an FDA-approved small-molecule prescription product. The product is regulated through the abbreviated new drug application pathway for therapeutically equivalent generics where the dosage form, strength, route and relevant performance characteristics match the reference product. [1,2]

The core regulatory requirements include:

• Pharmaceutical equivalence
• Bioequivalence where applicable
• Assay and content uniformity
• Dissolution or other product-performance testing
• Microbial limits
• Preservative effectiveness for multidose liquids
• Stability through the proposed shelf life
• Suspension uniformity and redispersibility
• Container-closure compatibility
• Labeling consistent with the reference product

For an oral suspension, conventional plasma bioequivalence may be less informative because sucralfate has minimal systemic absorption. Product quality and comparative performance remain central. The sponsor must establish that the formulation delivers a consistent dose and has appropriate physical and microbiological stability.

A novel dosage form, new route, new indication or substantial formulation change could require a 505(b)(2) application rather than a standard ANDA. That pathway may support differentiated products but introduces higher development and regulatory costs. [3]

What is the Orange Book status of Carafate and sucralfate?

The Orange Book identifies FDA-approved drug products, therapeutic-equivalence evaluations and relevant patent or exclusivity information. [2] Carafate and generic sucralfate are treated as small-molecule drug products, not biologics.

The commercial implications are:

• No biosimilar pathway applies.
• Generic applicants generally use the ANDA pathway.
• Any remaining listed patent must be assessed for certification and potential Paragraph IV litigation.
• Product-specific exclusivity is unlikely to be the primary barrier for a mature product.
• Orange Book status must be checked for the exact reference product, strength and dosage form before filing.

When does Carafate lose exclusivity?

The original commercial exclusivity for sucralfate has expired by virtue of the product's age. Current entry risk is therefore driven by generic substitution, formulation economics and distribution access rather than basic molecule exclusivity.

A generic applicant should still review:

• Current Orange Book patent listings
• Pediatric exclusivity, if any
• Regulatory exclusivity attached to a specific product
• Litigation history involving the selected reference product
• Labeling differences between tablets and suspension
• State substitution rules and payer formulary treatment

Are there Paragraph IV challenges to Carafate?

Paragraph IV challenges are legally possible if a generic applicant certifies that a listed patent is invalid, unenforceable or not infringed. For a mature product such as Carafate, the likely risk is lower than for recently approved specialty drugs, but it cannot be eliminated without a current product-specific Orange Book and litigation review.

The most plausible dispute areas would involve:

• Suspension composition
• Particle-size limits
• Manufacturing processes
• Stability characteristics
• Packaging systems
• Specific method-of-use language

A generic tablet entrant may face less formulation complexity than a suspension entrant. A liquid product with a materially different vehicle may create greater product-performance and intellectual-property questions.

What manufacturing and IP barriers affect sucralfate products?

Manufacturing barriers

Sucralfate manufacturing requires control of:

• Active-powder flow and bulk density
• Particle-size distribution
• Moisture exposure
• Powder blending
• Tablet compression
• Suspension wetting
• Polymer hydration
• Mixing energy
• Fill-volume accuracy
• Bottle and cap compatibility

The suspension is more difficult to manufacture consistently than the tablet. A low-cost producer may achieve an acceptable assay but still fail on redispersibility, dose uniformity or long-term sedimentation.

Intellectual-property barriers

The highest-value protectable features are likely to be incremental:

• A stable, low-viscosity suspension
• A preservative-free unit-dose product
• A specific particle-size distribution
• A controlled-release or mucoadhesive presentation
• A reconstitutable powder with improved shelf life
• A package that limits dosing errors
• A formulation that reduces excipient intolerance

Such claims must be technically narrow enough to survive examination but commercially broad enough to cover competing manufacturing approaches.

What commercial opportunities exist for Carafate excipients?

1. Sugar-free and low-sorbitol suspension

A formulation with reduced sorbitol or an alternative sweetener could target patients who experience gastrointestinal intolerance from polyols. The product would need comparative palatability and stability data.

2. Unit-dose liquid packaging

Single-dose cups, sachets or oral syringes could address the four-times-daily regimen and reduce contamination from repeated bottle opening. Unit-dose packaging also supports hospitals, long-term-care facilities and outpatient infusion centers that dispense oral medicines under controlled administration.

3. Ready-to-use oral syringes

A premeasured 10-mL presentation could reduce dosing errors and improve administration for patients with dysphagia, caregivers and institutional users. The format would need to manage viscosity, syringeability and container-closure stability.

4. Powder for reconstitution

A dry formulation could improve shipping weight and potentially extend stability. The key technical issues would be rapid wetting, complete dispersion, accurate final volume and acceptable in-use stability after reconstitution.

5. Improved tablet presentation

Opportunities include:

• Smaller-dose tablets taken in multiples
• More swallowable tablet geometry
• Orally dispersible or rapidly dispersing products
• Blister packaging for scheduled administration
• Reduced tablet friability at high drug load

These products may require a 505(b)(2) strategy if they do not fit conventional ANDA expectations.

6. Veterinary sucralfate products

Sucralfate is used in veterinary medicine, where liquid administration and dose flexibility are important. Commercial opportunities include flavored suspensions, oral syringes and species-specific packaging. Veterinary products require separate regulatory and commercialization strategies, and human-product labeling cannot simply be transferred to animal use.

How does Carafate compare with competing ulcer-protection products?

Product category	Active ingredient	Main advantage	Excipient opportunity
Carafate/sucralfate	Sucralfate	Local barrier action	Suspension stability and dosing convenience
Proton-pump inhibitors	Omeprazole, pantoprazole and others	Strong acid suppression	Delayed-release protection and pediatric liquids
H2 blockers	Famotidine and others	Oral convenience and lower complexity	Taste masking and chewable forms
Bismuth products	Bismuth subsalicylate or subcitrate	Mucosal and antimicrobial effects in selected settings	Suspension palatability and staining control
Alginate products	Alginate combinations	Physical reflux barrier	Foam and raft formation

Carafate competes poorly on dosing frequency and administration complexity. It retains a formulation advantage where local mucosal protection is clinically preferred or where acid suppression is not the central treatment objective.

Which companies are challenging the Carafate market?

Competition comes primarily from generic pharmaceutical manufacturers rather than from a single direct branded rival. The market structure favors companies with:

• Low-cost oral solid-dose capacity
• Suspension manufacturing capability
• Established retail-pharmacy distribution
• Institutional and hospital contracts
• Ability to maintain reliable supply of high-volume excipients
• Experience with ANDA supplements and manufacturing transfers

The most defensible position is likely to come from a differentiated liquid or packaging platform rather than another undifferentiated 1-gram tablet.

What licensing deals and partnership models are commercially viable?

A sucralfate opportunity may support several transaction structures:

1. Finished-dose licensing: A formulation developer licenses a ready-to-file suspension or unit-dose product to a generic company.
2. Technology licensing: The licensor provides a stabilizing polymer system, particle-size process or packaging technology.
3. Contract manufacturing: A sponsor uses a specialized liquid manufacturer to avoid capital expenditure.
4. Co-development: A generic company funds regulatory development while the formulation owner contributes know-how and receives milestones or royalties.
5. Veterinary licensing: A human pharmaceutical manufacturer licenses a flavored liquid platform to an animal-health company.

The most valuable asset is likely to be a reproducible formulation package with scale-up data, analytical methods, stability data and a clear regulatory pathway. A composition concept without manufacturing evidence has limited licensing value.

What generic launch scenarios exist for sucralfate?

Scenario 1: Commodity tablet entry

This is the lowest-risk model. It requires efficient manufacturing and broad distribution but offers limited differentiation and substantial price pressure.

Scenario 2: Generic oral suspension

This model has higher technical and operational risk but may support better margins because fewer manufacturers are willing to manage suspension performance, microbial controls and liquid supply chains.

Scenario 3: Differentiated unit-dose suspension

This model targets hospitals, long-term-care providers and adherence-sensitive patients. Packaging costs rise, but dosing accuracy and administration convenience can support contract-based pricing.

Scenario 4: 505(b)(2) reformulation

A new vehicle, delivery device, administration schedule or indication could create a differentiated product. Development expense and regulatory risk are higher, but the product may avoid direct commodity pricing.

How strong is the Carafate patent estate?

The estate is weak as a barrier to conventional generic entry because the product and active ingredient are old. Strength may remain in narrow formulation, process or packaging claims if any are currently enforceable and properly listed or otherwise actionable.

Estate element	Relative strength
Active ingredient	Very low
Standard 1-gram tablet	Low
Conventional suspension	Low to moderate, depending on claim scope
Advanced suspension system	Moderate if technically distinct
Unit-dose packaging	Moderate if supported by valid claims
New indication or dosing regimen	Product-specific and potentially higher
Manufacturing know-how	Often more important than patents

What is the revenue exposure for branded and generic Carafate?

Carafate revenue is unlikely to be separately visible in public reporting where the owner aggregates products by therapeutic area or business segment. The economic exposure is concentrated in prescription volume, generic substitution rates, payer reimbursement and dosage-form mix.

A tablet-only strategy generally faces severe price erosion. A suspension strategy can preserve value through lower supplier density and higher manufacturing complexity. Unit-dose and institutional products may generate better contractual economics than standard retail bottles, although packaging and distribution costs are higher.

Key Takeaways

• Carafate is sucralfate, an old small-molecule gastrointestinal product with no biosimilar risk.
• The principal commercial opportunity is formulation execution, especially for oral suspensions.
• Hydroxyethyl cellulose, xanthan gum and microcrystalline cellulose-carboxymethylcellulose systems are central to suspension performance.
• Sugar-free, low-sorbitol, unit-dose and oral-syringe presentations offer the clearest differentiation.
• Generic tablets are easier to launch but face stronger price erosion.
• Suspension products have higher manufacturing risk and potentially better margins.
• The practical competitive barrier is suspension quality, supply reliability and regulatory execution.
• Paragraph IV risk must be assessed against the current Orange Book record for the exact reference product.
• Veterinary and institutional channels offer adjacent opportunities.
• A formulation package with scale-up, stability and analytical data has greater licensing value than an unvalidated excipient concept.

FAQs About Carafate Excipient and Commercial Strategy

Can sucralfate be formulated without parabens?

Yes. A preservative-free or alternative-preservative formulation is technically possible, but the product would require appropriate microbial-control, stability and packaging data. Unit-dose packaging may support the strategy.

Is sucralfate suitable for an orally disintegrating tablet?

A conventional orally disintegrating tablet is challenging because sucralfate requires a high drug load. Tablet mass, mouthfeel and residual mineral texture would need careful optimization.

What is the best packaging for a sucralfate suspension?

A multidose bottle is the lowest-cost option. Unit-dose cups or prefilled oral syringes offer greater dosing convenience and lower contamination risk but increase packaging cost.

Does sucralfate require a bioequivalence study for an ANDA?

The regulatory approach depends on dosage form and product characteristics. Because systemic absorption is limited, comparative in vitro performance, product quality and other FDA-accepted evidence may be central for an oral suspension. [2,3]

Can a sucralfate formulation support a 505(b)(2) application?

Potentially. A materially differentiated dosage form, delivery system, formulation, route or indication may support a 505(b)(2) pathway, subject to FDA determination and the evidence required for the proposed changes.

References

1. U.S. Food and Drug Administration. (2023). Carafate (sucralfate) tablets and oral suspension prescribing information. FDA-approved labeling.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
3. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). FDA guidance and regulatory materials.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Center for Drug Evaluation and Research.